Skip to main content Accessibility help
×
Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-29T00:15:53.206Z Has data issue: false hasContentIssue false

10 - Open Source drug discovery: a revolutionary paradigm or a Utopian model?

Published online by Cambridge University Press:  04 August 2010

Thomas Pogge
Affiliation:
Yale University, Connecticut
Matthew Rimmer
Affiliation:
Australian National University, Canberra
Kim Rubenstein
Affiliation:
Australian National University, Canberra
Get access

Summary

Introduction

The success of Open Source software has attracted much attention and the applicability of Open Source models in non-software contexts has been proposed as an alternative innovation model and as a solution to some of the problems with the current intellectual property system. In recent years the applicability of Open Source models for drug discovery and development has been discussed in academic literature. Although there is much scepticism about the proposal to extend Open Source models/licences to non-software contexts, there is a growing interest in applying them in fields like biology and biotechnology, partly because of the success of non-proprietary initiatives like the SNP Consortium and the HapMap project and also because of initiatives like BIOS. In this chapter it is suggested that Open Source drug discovery (‘OSDD’) is a workable idea that deserves support to enable it to be tested in the real world. It is also contended that OSDD can be used with other initiatives to overcome the twin problems of access and affordability, although at this time one cannot assert that OSDD is always compatible with other proposals. Finally, OSDD is no panacea for all of the problems with pharmaceutical innovation, access and affordability. Its potential is untested but in the long run it may emerge as a workable model in drug discovery for neglected diseases and as a framework that is well suited for co-operation among developing countries in finding cures for diseases in those countries.

Type
Chapter
Information
Incentives for Global Public Health
Patent Law and Access to Essential Medicines
, pp. 263 - 283
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×